Cetera Investment Advisers
CAPR icon

Cetera Investment Advisers’s Capricor Therapeutics CAPR Stock Holding History

Cetera Investment Advisers’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Buy
7,342
+149
+2% +$3.97K ﹤0.01% 4211
2025
Q4 		$208K Sell
7,193
-3,393
-32% -$44.3K ﹤0.01% 4208
2025
Q3 		$76.3K Buy
+10,586
New +$77.9K ﹤0.01% 4373

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cetera Investment Advisers's CAPR Position: Q1 2026 in Review

Cetera Investment Advisers increased its Capricor Therapeutics (CAPR) stake by 2.1% in Q1 2026, buying an estimated $3.97K and bringing the position to 7,342 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #4211.

Cetera Investment Advisers first reported a position in CAPR in Q3 2025 and has held it in 3 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Cetera Investment Advisers held 7,342 shares of Capricor Therapeutics worth $223K as of Q1 2026.
  • Cetera Investment Advisers bought 149 Capricor Therapeutics shares in Q1 2026, an estimated $3.97K.
  • Capricor Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #4211 holding.
  • Cetera Investment Advisers first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.